Structures by: Averkiev B. B.
Total: 18
5,6-Bis(9<i>H</i>-carbazol-9-yl)benzo[<i>c</i>][1,2,5]thiadiazole
C30H18N4S
Acta Crystallographica Section C (2017) 73, 4 319-324
a=8.3617(8)Å b=8.7261(8)Å c=8.8590(8)Å
α=104.4510(10)° β=94.1870(10)° γ=112.3440(10)°
5,6-Bis(9<i>H</i>-carbazol-9-yl)benzo[<i>c</i>][1,2,5]thiadiazole 0.125-hydrate
C30H18N4S,0.125(H2O1)
Acta Crystallographica Section C (2017) 73, 4 319-324
a=28.338(3)Å b=12.9466(12)Å c=26.799(3)Å
α=90° β=113.3360(10)° γ=90°
<i>N</i>,<i>N</i>,<i>N</i>-Triethylhydroxylammonium chloride
C6H16NO,Cl
Acta Crystallographica Section E (2016) 72, 11 1607-1609
a=12.816(5)Å b=6.371(3)Å c=10.439(4)Å
α=90° β=90° γ=90°
5,6,7,8,13,14-hexahydrobis[1,2,5]oxadiazolo[3,4-b:3',4'-f] [1,8,4,5]dioxadiazacyclododecine
C8H10N6O4
Acta Crystallographica Section C (2004) 60, 7 o520-o523
a=8.3331(12)Å b=14.695(2)Å c=9.2384(13)Å
α=90.00° β=106.619(3)° γ=90.00°
4-[2-(2-{2-[(4-amino-1,2,5-oxadiazol-3-yl)oxy]ethoxy}ethoxy)ethoxy]- 1,2,5-oxadiazol-3-amine
C10H16N6O6
Acta Crystallographica Section C (2004) 60, 7 o520-o523
a=31.363(6)Å b=6.0550(12)Å c=15.724(3)Å
α=90.00° β=98.34(3)° γ=90.00°
(E)-(4-methoxyphenyl)(4-nitrophenyl)diazene
C13H11N3O3
Acta Crystallographica Section C (2002) 58, 10 o624-o628
a=6.1530(12)Å b=7.5500(15)Å c=13.683(3)Å
α=100.80(3)° β=102.68(3)° γ=91.74(3)°
(E)-[4-(6-bromohexyloxy)phenyl](4-cyanophenyl)diazene
C19H20BrN3O
Acta Crystallographica Section C (2002) 58, 10 o624-o628
a=7.4279(18)Å b=12.009(3)Å c=19.552(5)Å
α=86.502(5)° β=80.511(5)° γ=87.604(5)°
Bis(3-cyanofurazan-4-yl) ether
C6N6O3
Acta Crystallographica Section C (2003) 59, 7 o383-o387
a=13.639(3)Å b=8.899(2)Å c=6.9254(17)Å
α=90.00° β=97.13(2)° γ=90.00°
3-cyanofurazanyl 3-nitrofurazanyl ether
C5N6O5
Acta Crystallographica Section C (2003) 59, 7 o383-o387
a=7.853(2)Å b=8.791(2)Å c=12.229(3)Å
α=90.00° β=90.00° γ=90.00°
3,4-bis(3-cyanofurazan-4-yloxy)furazan
C8N8O5
Acta Crystallographica Section C (2003) 59, 7 o383-o387
a=7.8295(15)Å b=8.6273(18)Å c=17.409(3)Å
α=90.00° β=90.00° γ=90.00°
Bis[3-(3-cyanofurazan-4-yloxy)furazan-4-yl]diazene
C10N12O6
Acta Crystallographica Section C (2003) 59, 7 o383-o387
a=6.4300(13)Å b=13.709(3)Å c=17.134(3)Å
α=90.00° β=90.00° γ=90.00°
4,4'-dimethylazoxyfurazan
C6H6N6O3
Crystal Growth & Design (2005) 5, 2 631
a=6.947(2)Å b=6.246(2)Å c=10.760(3)Å
α=90.00° β=104.23(2)° γ=90.00°
4,4'-Dichloroazoxyfurazan
C4Cl2N6O3
Crystal Growth & Design (2005) 5, 2 631
a=6.9770(14)Å b=6.1540(12)Å c=10.515(2)Å
α=90.00° β=108.49(3)° γ=90.00°
4,4'-di(morpholin-1-yl)azoxyfurazan
C12H16N8O5
Crystal Growth & Design (2005) 5, 2 631
a=6.7202(14)Å b=8.4002(17)Å c=13.938(3)Å
α=94.599(17)° β=101.385(16)° γ=94.682(16)°
C14H17N3S
C14H17N3S
Crystal Growth & Design (2004) 4, 6 1265
a=9.1670(18)Å b=13.023(3)Å c=12.172(2)Å
α=90.00° β=93.97(3)° γ=90.00°
C14H17N3S
C14H17N3S
Crystal Growth & Design (2004) 4, 6 1265
a=8.753(4)Å b=8.890(4)Å c=10.830(5)Å
α=85.44(4)° β=69.76(3)° γ=63.65(3)°
4(C14H17N3S)C2H3N
4(C14H17N3S)C2H3N
Crystal Growth & Design (2004) 4, 6 1265
a=39.370(8)Å b=8.8800(18)Å c=17.056(3)Å
α=90.00° β=101.19(3)° γ=90.00°
(E)-(4-hydroxyphenyl)(4-nitrophenyl)diazene
C12H9N3O3
Acta Crystallographica Section C (2002) 58, 10 o624-o628
a=7.290(4)Å b=10.648(6)Å c=28.353(16)Å
α=93.685(10)° β=94.922(11)° γ=100.811(10)°